D. E. Shaw & Co., Inc. Sage Therapeutics, Inc. Put Options Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$7.02 - $13.08 $35,100 - $65,400	-5,000 Reduced 10.85%	41,100 $296,000
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $487,738 - $825,189	46,100 New	46,100 $500,000
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $1.69 Million - $2.51 Million	-55,000 Reduced 73.33%	20,000 $662,000
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $2.47 Million - $3.57 Million	45,000 Added 150.0%	75,000 $4.26 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $51,900 - $86,300	-2,000 Reduced 6.25%	30,000 $1.25 Million
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $446,650 - $818,250	-5,000 Reduced 13.51%	32,000 $5.09 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $1.35 Million - $2.31 Million	16,500 Added 80.49%	37,000 $3.54 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $690,550 - $845,200	5,000 Added 32.26%	20,500 $2.9 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $70,180 - $87,880	500 Added 3.33%	15,500 $2.43 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $2.28 Million - $2.88 Million	15,000 New	15,000 $2.42 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $303M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.